(NASDAQ: CODX) Is Our Top Watch Today. Here's Why:

Co-Diagnostics has recently shifted investor attention toward the commercialization phase of its proprietary PCR platform. One of the company's biggest milestones came with the completion of clinical and analytical studies for its Co-Dx™ PCR Flu A/B & RSV point-of-care test, paving the way for a planned FDA 510(k) submission in Q3 2026. At the same time, its international expansion continues to accelerate through joint ventures in India and Saudi Arabia, giving investors multiple potential catalysts beyond the U.S. market. The company is transitioning from a COVID-era diagnostics story into a broader molecular diagnostics platform targeting respiratory illnesses, tuberculosis, Ebola, and other infectious diseases.

Demand for Co-Diagnostics' technology is driven by the global need for fast, accurate, and decentralized molecular testing. Traditional PCR testing often requires centralized laboratories, expensive equipment, and long turnaround times. Co-Diagnostics is addressing these bottlenecks with its portable Co-Dx PCR platform, designed for point-of-care settings while maintaining laboratory-quality molecular testing. The company is also targeting underserved international markets where rapid diagnostics can significantly improve disease detection and outbreak response, giving it exposure to both developed and emerging healthcare systems.

Co-Diagnostics is a molecular diagnostics company headquartered in Salt Lake City, Utah. The company develops, manufactures, and commercializes PCR-based diagnostic technologies used to detect infectious diseases through DNA and RNA analysis. Beyond laboratory testing, Co-Diagnostics is building a portfolio of point-of-care PCR systems intended for clinics, physician offices, and home use, while also expanding into genetic marker discovery and other molecular applications.

Co-Diagnostics differentiates itself through its proprietary PCR chemistry and integrated diagnostic platform designed to make molecular testing faster, more accessible, and easier to deploy outside of traditional laboratories. Unlike many diagnostics companies focused on a single disease, Co-Diagnostics is developing a scalable platform supporting multiple test menus—including respiratory infections, tuberculosis, Ebola, and future assays—while expanding globally through strategic joint ventures like CoSara in India and CoMira in Saudi Arabia. This combination of platform technology, international partnerships, and point-of-care accessibility gives the company multiple avenues for long-term growth if regulatory milestones are achieved and commercialization continues successfully.

Disclaimer: Sponsored Content

Trader's Incentive is a subsidiary of Parabolic Equities LLC (the “Publisher”). The Publisher received Six Thousand USD in cash via wire transfer from Bullish Media LLC ("Bullish Media") for a one day campaign beginning and ending on July Twenty Eighth Twenty Twenty Six, before the deduction of any applicable bank wire, PayPal, Wise, or electronic payment processing fees, in exchange for the publication and dissemination of the Information (as defined in the full disclaimer linked below). Bullish Media LLC, in turn, received funding acting on behalf of and with funding provided by the Issuer. All compensation received is strictly cash. Neither the Publisher nor Bullish Media LLC received any equity compensation, stock options, warrants, or securities-based consideration of any kind from the Issuer or any intermediary. Read the full disclaimer here: